Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
The companies have taken a different label-expansion approach to rivals Johnson & Johnson and Bayer, but all are hoping for a win in cancer patients.
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
Since becoming a pure-play health tech group Philips has been buying like crazy. Might Siemens Healthineers and GE Healthcare join in?
Nash, the one-time favourite therapy area for biopharma speculators, is back.
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
Novo Nordisk's cell therapy collaborations are a sign that serious work is under way.
The amyloid hypothesis of Alzheimer's has taken another battering – and some companies are finally taking a new approach.
Despite government rhetoric, the US biosimilar market has failed to live up to expectations so far.